Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.66M | 2.44M | 2.09M | 925.00K | 725.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.65M | 5.75M | 5.62M | 4.02M | 3.65M |
| Operating Income | -5.65M | -5.75M | -5.62M | -4.02M | -3.65M |
| Income Before Tax | -5.93M | -4.89M | -6.92M | -4.07M | -3.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.93 | -4.89 | -6.92 | -4.07 | -3.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.93M | -4.89M | -6.92M | -4.07M | -3.67M |
| EBIT | -5.65M | -5.75M | -5.62M | -4.02M | -3.65M |
| EBITDA | -5.64M | -5.69M | -5.57M | -3.96M | -3.59M |
| EPS Basic | -0.20 | -0.17 | -0.24 | -0.15 | -4.99 |
| Normalized Basic EPS | -0.14 | -0.11 | -0.15 | -0.10 | -3.13 |
| EPS Diluted | -0.20 | -0.17 | -0.24 | -0.15 | -4.99 |
| Normalized Diluted EPS | -0.14 | -0.11 | -0.15 | -0.10 | -3.13 |
| Average Basic Shares Outstanding | 117.93M | 117.40M | 115.54M | 123.32M | 93.48M |
| Average Diluted Shares Outstanding | 117.93M | 117.40M | 115.54M | 123.32M | 93.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |